The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,701–1,800 of 2,716
Trastornos de la glándula suprarrenal: diagnóstico y tratamiento
Verónica, Q. A. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70222-0 · Cited by 7
“Sin embargo, aún no hay consenso para su utilización en el diagnóstico diferencial del SC ACTH dependiente (2).”
Andersen, M., Ganc-Petersen, J., Jørgensen, J. O. L., et al. (2010) · Clinical and investigative medicine · doi:10.25011/cim.v33i3.13727 · Cited by 3
Hyperandrogenism produced by ovarian tumors in women at different life stages.
Otta, C. F., de Mereshian, P. S., de Corominas, M. L., Fuster, M., & Lopez, C. R. E. C. (2014) · Revista de la Facultad de Ciencias Médicas de Córdoba · doi:10.31053/1853.0605.v71.n2.9082 · Cited by 4
Screening for ACTH-dependent hypercortisolism in patients with pituitary incidentaloma
Torpy, D. J. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0058 · Cited by 3
LABORATORIO DE HORMONAS: ASPECTOS PRÁCTICOS
René Díaz, T., Jesús Véliz, L., & Nelson Wohllk, G. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.11.006 · Cited by 4
Update on Hypercortisolism Therapy
Arnaldi, G., & Trementino, L. (2016) · Frontiers of hormone research · doi:10.1159/000443869 · Cited by 3
Suspect myopathy? Take this approach to the work-up.
Smith, B. W., McCarthy, J. C., & Dawley, C. A. (2014) · PubMed · Cited by 4
A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.
Malek, M., Esfehanian, F., Amouzegar, A., Sarvghadi, F., Moosavi, Z., Mohajeri‐Tehrani, M. R., Khamseh, M. E., Amirbaigloo, A., & Valojerdi, A. E. (2016) · PubMed Central · Cited by 4
Características clínicas y demográficas de pacientes sometidos a cirugía bariátrica en Medellín
Rincón, A. R., Tirado, J. D. V., Otálvaro, A. F. T., Valencia, M. E., Sepúlveda, J. C. D., Parra, C. F. C., & Jonathan Cárdenas, C. (2016) · Medicina UPB · doi:10.18566/medupb.v35n2.a02 · Cited by 4
Uncomplicated Pregnancy in a Patient with Cushing's Disease
Doğanşen, S. Ç. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.215 · Cited by 3
“Endocrine Society Clinical Practice Guideline recommends the initial use of one test with high diagnostic accuracy (UFC, midnight salivary cortisol, 1 mg overnight or LDST, HDST) in CS (24).”
MethodAdrenal Causes of Cushing’s Syndrome
Cavagnini, F., & Giraldi, F. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00103-7 · Cited by 7
A paraneoplastic potassium and acid-base disturbance
Wiles, S. P., Kiczek, M. P., & Rutecki, G. W. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18014 · Cited by 4
A case of systemic lupus erythematosus complicated by subclinical Cushing’s syndrome: case report
Nakayama, Y., Taura, D., Shibue, K., Kuramoto, N., Mimori, T., & Inagaki, N. (2019) · Modern Rheumatology Case Reports · doi:10.1080/24725625.2019.1638049 · Cited by 3
“The patient was therefore diagnosed as having subclinical CS and was followed up without treatment [7].”
BackgroundCortisol: mediciones de laboratorio y aplicación clínica
Hernandez-Quiceno, S., Uribe-Bojanini, E., Velásquez, J. M. A., Campuzano‐Maya, G., & Salazar-Peláez, L. M. (2016) · Medicina y Laboratorio · doi:10.36384/01232576.74 · Cited by 13
Disorders of the adrenal gland
Bertholf, R. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818277-2.00004-2 · Cited by 3
Broeks, C. W., Kok, R., Choenni, V., Van, R., Hoogendijk, W. J. G., Hillegers, M. H. J., Kamperman, A. M., & den Berg, M. P. L. (2021) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2021.100078 · Cited by 4
Morning Serum Cortisol as a Predictor for the HPA Axis Recovery in Cushing’s Disease
Cui, Q., Liu, D., Xiang, B., Sun, Q., Fan, L., He, M., Wang, Y., Zhu, X., & Ye, H. (2021) · International Journal of Endocrinology · doi:10.1155/2021/4586229 · Cited by 3
Secondary PCOS: Well-defined causes, leading to the PCOS phenotype
Gambineri, A., Cecchetti, C., Altieri, P., Ribichini, D., Preiato, V. L., Fanelli, F., & Pagotto, U. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00008-0 · Cited by 4
Pituitary disease in pregnancy
Dworakowska, D., & Aylwin, S. J. B. (2012) · Series in maternal-fetal medicine · doi:10.3109/9781841847597.018 · Cited by 3
Kelsall, A., & Newell-Price, J. D. C. (2021) · Medicine · doi:10.1016/j.mpmed.2021.05.006 · Cited by 3
Self-citationEndocrine Disturbances Affecting Reproduction
Chang, A. Y., & Auchus, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00024-x · Cited by 5
Guignat, L., Assié, G., BERTAGNA, X. Y., & Bertherat, J. Y. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2008.10.008 · Cited by 4
Alexandraki, K., & Grossman, A. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8684-8_9 · Cited by 6
Endocrine and metabolic complications of advanced cancer
Bower, M., Robinson, L. A., & Cox, S. (2015) · doi:10.1093/med/9780199656097.003.0142 · Cited by 3
Yılmaz, N., Tazegül, G., Sarı, R., Avşar, E., Altunbaş, H., & Balcı, M. K. (2021) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2021.479 · Cited by 5
Yu, H. W., Cho, W. I., Chung, H. R., Choi, K. H., Yun, S., Cho, H. S., Shin, C. H., & Yang, S. W. (2016) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2016.21.1.47 · Cited by 3
Unger, N. (2018) · Der Chirurg · doi:10.1007/s00104-018-0739-6 · Cited by 4
Endocrine Hypertensive Emergencies
Eisenhofer, G., Januszewicz, A., Pamporaki, C., & Lenders, J. W. M. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch22 · Cited by 3
ACTH-Secreting Pituitary Tumors
Pivonello, R., Martino, M. C. D., Iacuaniello, D., Simeoli, C., & Colao, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.04102-7 · Cited by 3
Hamidi, O., St-Jean, M., Lacroix, A., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag095 · Cited by 5
ADENOMA HIPOFISÁRIO: CORRELAÇÃO CLÍNICA, LABORATORIAL E RADIOLÓGICA
Carneiro, C. C., Mendes, B. B., & Bastos, L. G. (2015) · Revista da Universidade Vale do Rio Verde · doi:10.5892/ruvrd.v13i1.1979 · Cited by 2
Uchida, T., Yamaguchi, H., Arimura, Y., Nagayama, A., Moritaka, K., Inoguchi, Y., Ashida, K., Nomura, M., Nakazato, M., & Shimoda, K. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0053 · Cited by 2
Jones, B. R., Shao, J., Sanghvi, M., Ayala, A. R., Luo, R., & Wang, J. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2360358 · Cited by 2
Bryk, A. H., Minasyan, M., Hubalewska–Dydejczyk, A., & Gilis‐Januszewska, A. (2024) · Endocrine Connections · doi:10.1530/ec-23-0557 · Cited by 5
“Diagnosis of CS was based on elevated 24-h urinary UFC, elevated midnight cortisol levels, and cortisol concentrations greater than 1.8 μg/dL following a 1 mg dexamethasone suppression test (12, 21).”
MethodInfluentialMoleta, F. B., Lobe, M. C. S., Nesi-França, S., de Lacerda, L., & Pereira, R. M. (2024) · Hormone Research in Paediatrics · doi:10.1159/000540706 · Cited by 2
“However, the evaluation of glucocorticoids in many cases consisted only of 17-OHCS or free urinary cortisol, both of which have lower sensitivity than the dexamethasone suppression test for detecting hy-percortisolism of adrenal origin [37, 38].”
Neoplastic hypercortisolism: Cut-off values for late-night salivary cortisol & cortisone
Koops, K., Bisschop, P. H. L. T., Heijboer, A. C., & Hillebrand, J. J. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120310 · Cited by 3
Lionetto, L., Bernardini, D. D., Costanzi, G., Maggio, R., Aloini, M. E., Roberto, G., Ricci, F., Biondo, I., Lardo, P., Salerno, G., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.04.035 · Cited by 3
Zawadzka, K., Calissendorff, J., Rzepka, E., Pędziwiatr, M., Hubalewska–Dydejczyk, A., & Falhammar, H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf361 · Cited by 4
Iwamoto, Y., Kimura, T., Morimoto, Y., Sugisaki, T., Dan, K., Iwamoto, H., Sanada, J., Fushimi, Y., Shimoda, M., Fujii, T., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej25-0132 · Cited by 2
Klahr, J. D., Carroll, T. B., Nerenz, R. D., & Raff, H. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.07.008 · Cited by 3
“10,12 A higher burden of false-positive results complicates diagnosis, leading to further testing, delays in diagnosis and treatment, and increased costs and resource utilization for both patients and the health care system.”
InfluentialCurrent challenges in Cushing's syndrome testing: blood, saliva, urine, or hair?
Ferrière, A., & Tabarin, A. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000923 · Cited by 3
Forte, A., D’Elia, L., Luca, C. D., Fiore, A., Barbato, A., Abate, V., Vergatti, A., Verde, N., FILIPPO, G. D., Venetucci, P., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1495930 · Cited by 2
Akkuş, G., Aksoydan, Ü. P., Odabaş, F., Binokay, H., Sert, M., & Tetıker, T. (2025) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/0115734056347340241009102228 · Cited by 2
Sharifi, G., Paraandavaji, E., Dilmaghani, N. A., et al. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100417 · Cited by 2
“Low-dose dexamethasone suppression testing was performed using the 2 mg/48 h protocol, which was the standard practice in our institution during the study period (2010 onward) [8].”
Changing face of Cushing’s disease over three decades in pituitary center
Muradov, İ., Şahin, S., Uysal, S., Sulu, C., Gunebakan, P., Tunc, A., Kocaman, B. B., Soltanova, L., Gazioğlu, N., Tanrıöver, N., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02702-5 · Cited by 3
Ishibashi, Y., Baba, R., Okada, A., Otagaki, Y., Kodama, T., Egusa, G., Nagano, G., Matsuda, T., Miura, R., Ono, A., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1683546 · Cited by 2
Prevalence of Hypercortisolism in Hypertension and Its Link to Carotid Atherosclerosis Markers
Musolino, A., Parazzoli, C., Donne, E. D., Favero, V., Aresta, C., Bilo, G., Croce, A., Pengo, M. F., Parati, G., Persani, L., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.10.013 · Cited by 6
Krzystek, Ł., Sagan, K. P., Andrysiak-Mamos, E., Retfiński, S., Buć, K., Marczak, W., Brzeska, A., Patalong-Wójcik, M., Żochowska, E., Dąbkowski, K., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1700273 · Cited by 3
“The gold standard for the management of CS is surgical resection of the primary lesion responsible for excessive ACTH or cortisol production, which offers the potential for complete remission (8).”
Reincke, M., Apaydın, T., Kakashvili, M., Albert, N. L., Thorsteinsdottir, J., Schweizer, J. R. D. O. L., Theodoropoulou, M., Schilbach, K., & Völter, F. (2026) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2728 · Cited by 3
“Despite its low incidence (approximately 2–3 cases per million person-years), endogenous CS is often over-investigated because obesity, hypertension, and metabolic syndrome are common in the general population [2].”
Chen, X., Wang, D., Tao, J., & Zhang, A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103067 · Cited by 3
Semiconducting few-layer 2D-borophene based impedimetric sensor for cortisol detection
Gupta, G. H., & Kumar, S. (2026) · Sensors and Actuators A Physical · doi:10.1016/j.sna.2026.117852 · Cited by 3
di Filippo, L., Frara, S., Terenzi, U., Menotti, S., Mortini, P., & Giustina, A. (2026) · Pituitary · doi:10.1007/s11102-026-01674-w · Cited by 3
“CD was diagnosed according to current guidelines [1, 29], based on elevated 24-hours urinary free cortisol, abnormal late-night salivary cortisol and/or lack of 8AM serum cortisol suppression after 1-mg overnight dexamethasone suppression test (DST), followed by pituitary MRI and, when indicated,…”
Biagetti, B., Marques, P., Soto‐Moreno, A., García-Centeno, R., Fernández, L. G., García, M. D. O., Echarri, A. I., Cardona-Arias, A., Rodríguez, M. D. M., Paja, M., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag187 · Cited by 3
Kuzu, İ., Zuhur, S. S., Özel, A., et al. (2015) · Endocrine Practice · doi:10.4158/ep151060.or · Cited by 2
Hipercortisolismo de origen adrenal
Guillín, C., Bernabéu, I., Rodríguez-Gómez, I. A., & Casanueva, F. F. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.06.011 · Cited by 2
Sandner, B., & Kratzsch, J. (2017) · Journal of Laboratory Medicine · doi:10.1515/labmed-2017-0004 · Cited by 2
Bisogni, V., Maiolino, G., Ceolotto, G., Pengo, M. F., Marchese‐Ragona, R., Artusi, C., Brugnolo, L., Lerco, S., Borsetto, D., Gaudioso, P., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0113 · Cited by 3
Telomere Length Changes in Children With Cushing Disease: A Pilot Study
Tatsi, C., Flippo, C. L., Faucz, F. R., Sinaii, N., & Stratakis, C. A. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa067 · Cited by 2
Cushing syndrome with acute kidney injury due to ureteral stones in a 6-year-old boy
Song, K., Kwon, A., Suh, J., Choi, H. S., Chae, H. W., & Kim, H.-S. (2020) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040026.013 · Cited by 2
Gosavi, V., Lila, A. R., Memon, S. S., Sarathi, V., Thakkar, K., Dalvi, A. N., Malhotra, G., Prakash, G. J., Patil, V. A., Shah, N. S., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1735-3232 · Cited by 3
“Moon facies with plethora, easy bruising, wide livid striae, proximal myopathy, and weight gain with reduced growth velocity in children were considered as discriminatory signs of CS (DSCS) [11].”
BackgroundInfluentialJuan, M. D. S., Lagamayo, D., Carnate, J. M., & Joven, M. H. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-248525 · Cited by 2
Tatsi, C., Saidkhodjaeva, L., Flippo, C. L., & Stratakis, C. A. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac080 · Cited by 2
Sulu, C., KAYNAK, G. K., KÖSKÜN, T., Koca, O., Icli, T. B., Kavla, Y., Özkaya, H. M., Turan, Ş., Eskin, M., & Kadıoğlu, P. (2022) · Pituitary · doi:10.1007/s11102-022-01275-3 · Cited by 2
“The remaining patients with a clear-cut diagnosis of CD according to the Endocrine Society Guideline were approached by phone [31].”
MethodEvaluation and Management of Hypertension in Children
Larkins, N., Lurbe, E., & Flynn, J. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_123 · Cited by 2
Balderrama-Soto, A., Rivera-Hernández, A. D. J., Reza-Albarrán, A. A., la Vega, A. N.-D., Vergara-López, A., Monteros-Sánchez, A. L. E. D. L., Navas-Minero, C. E., Abreu-Rosario, C., Ramos, D. C., Espinosa-Cárdenas, E., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000025 · Cited by 6
Watanabe, D., Morimoto, S., Morishima, N., & Ichihara, A. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02309-x · Cited by 3
“Endo-crine tests for CS showed a lack of diurnal rhythm in serum cortisol levels (> 7.5 µg/dL at midnight), no suppression of serum cortisol levels (> 5 µg/dL) after low-dose (1 mg) dexamethasone suppression test, and increased 24 h urinary free cortisol excretion [16].”
InfluentialMetastatic Merkel Cell Carcinoma Within a Cortisol-producing Adrenal Adenoma
Cutrone, L. S., Subauste, J. S., Gómez-Sánchez, C. E., et al. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad100 · Cited by 2
Two Cases of Surreptitious Steroid Use Uncovered Utilizing Urine Synthetic Glucocorticoid Testing
Pape, B. J., & Kern, P. A. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad132 · Cited by 2
“The workup for endogenous Cushing syndrome includes screening tests, followed by additional studies to determine if cortisol is ACTH-dependent, and ultimately imaging of the pituitary, adrenals, or sampling from the inferior petro-sal sinus or adrenal veins [1, 2].”
BackgroundVoltan, G., Antonelli, G., Mondin, A., Tizianel, I., Sabbadin, C., Barbot, M., Basso, D., Scaroni, C. M., & Ceccato, F. (2023) · Endocrine · doi:10.1007/s12020-023-03597-z · Cited by 2
“There are several applications of salivary F, for example in the diagnosis of Cushing ’ s syndrome [26], but also in the follow-up of patients with Cushing ’ s disease, to detect relapse after surgical remission and while on medical therapy [1].”
BackgroundKousoula, K., Ragnarsson, Ó., & Trimpou, P. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad160 · Cited by 2
“The Endocrine Society Clinical Practice Guidelines for the diagnosis of CS recommend that exogenous CS be always excluded before starting the investigation of endogenous CS (9).”
MethodTrummer, C., Pandis, M., Theiler‐Schwetz, V., Schmitt, L., Obermayer-Pietsch, B. M., Gellner, V., Simon, A., & Pilz, S. (2024) · Endocrine · doi:10.1007/s12020-024-03832-1 · Cited by 2
“In this group, CS was ruled out clinically and/or biochemically before surgery [20].”
BackgroundMethodBone mineral density in patients with Cushing’s syndrome
Seker, A., & Yavuz, D. G. (2024) · Marmara medical journal · doi:10.5472/marumj.1485351 · Cited by 2
Du, Q.-W., Li, X., Zheng, L., Dong, L., Liu, F., & Liang, P. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_2315_23 · Cited by 2
Ectopic adrenocorticotropic hormone syndrome in patients with olfactory neuroblastoma
Mikoshiba, T., Sekimizu, M., Saito, S., et al. (2024) · Endocrine Related Cancer · doi:10.1530/erc-24-0030 · Cited by 2
Valizadeh, M., Rahmani, F., Nikoohemmat, M., Ahmadi, A. R., Hosseinpanah, F., Niroomand, M., Bagheri, A. K., Grossman, A. B., & Abiri, B. (2024) · Endocrine Research · doi:10.1080/07435800.2024.2381720 · Cited by 4
“11 However, some patients with EAS may yield false-positive results in response to the HDDST and other dynamic tests.”
Dorizzi, R. M., SIPMeL, A. N. D. G.-E. E. E., Brescia, V., Vitillo, M., Porzio, O., & D’Aurizio, F. (2024) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.24.00249-4 · Cited by 2
Investigating secondary hypertension in cerebrovascular disease
Zeicu, C., Fisk, M., & Evans, N. R. (2024) · Practical Neurology · doi:10.1136/pn-2024-004169 · Cited by 4
Moreno, J. M. M., Valverde, N. N. G., Muedas-Porras, G., Nombera-Aznarán, M., Aguilar-Figueroa, F., & Gulati, M. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000805 · Cited by 3
Kuckuck, S., van der Valk, E. S., Lengton, R., März, J., Hillegers, M. H. J., Penninx, B. W. J. H., Kavousi, M., Boon, M. R., van den Berg, S. A. A., & van Rossum, E. F. C. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107224 · Cited by 3
“…of extremely high exogenous and endogenous glucocorticoid overexposure with weight gain and cardiometabolic deterioration, as observed in consequence of prolonged systemic glucocorticoid medication use and disease states such as Cushing ’ s syndrome (Van der Valk et al., 2018; Nieman et al., 2008).”
BackgroundLateralization outcomes of bilateral inferior petrosal sinus sampling: desmopressin vs CRH
Erkan, B., Cil, M. S., Cingöz, M., Burhan, Ş., Aksoy, Ş., Yüzkan, S., Akpınar, E., Demir, S., Tanrıverdi, O., Koçak, B., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00620-4 · Cited by 2
“In rarer instances, the etiology may involve ectopic ACTH secretion or tumors that secrete ectopic corticotropin-releasing hormone (CRH) [ 3 , 4].”
Tsujimoto, Y., Yamamoto, N., Bando, H., Yamamoto, M., Ohmachi, Y., Motomura, Y., Oi-Yo, Y., Sasaki, Y., Suzuki, M., Urai, S., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1511155 · Cited by 3
Agrawal, N., Sinha, A., Chakraborty, P. P., Bhattacharjee, R., Awasthi, A., & Maiti, A. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_482_23 · Cited by 3
Long-term cardiometabolic outcomes of primary bilateral macronodular adrenal hyperplasia
Zhou, H., Zhang, P., Yin, Y., Liu, L., Li, J., Xu, H., Yu, F., Su, X., Lyu, Z., Gu, W., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02561-0 · Cited by 2
Lee, M. H., & Lee, T. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111279 · Cited by 2
Diagnosis of Cushing’s Disease
Elenius, H., & Nieman, L. K. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.06.001 · Cited by 4
Self-citationMazzeo, P., Bovo, G., Mondin, A., Voltan, G., Manara, R., Caccese, M., Denaro, L., Ceccato, F., & Barbot, M. (2025) · Pituitary · doi:10.1007/s11102-025-01579-0 · Cited by 2
Arslan, F. D., & HOFFMANN, G. E. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0984 · Cited by 2
“In addition, the Endocrine Society recognizes the variation of analytic performance that can lead to misinterpretations of threshold values used for Cushing ’ s syndrome [8].”
Kitamura, Y., Yokomoto‐Umakoshi, M., Nakano, Y., Nakatani, K., Umakoshi, H., Nakao, H., Kaneko, H., Iwahashi, N., Fujita, M., Ogasawara, T., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf632 · Cited by 1
Unmasking Hypercortisolism in Difficult-to-Control Type 2 Diabetes: A Useful Paradigm Shift?
Nieman, L. K., & Muniyappa, R. (2025) · Diabetes Care · doi:10.2337/dci25-0038 · Cited by 2
Self-citationBhansali, A. K., Aggarwal, A., Parthan, G., & Gogate, Y. (2016) · Springer eBooks · doi:10.1007/978-81-322-2815-8_4 · Cited by 2
Severe metabolic alkalosis–a diagnostic dilemma
FORAY, N. E., Stone, T., Johnson, A. A. T., Ali, M. A., Kulkarni, S., Gao, J., & Sreedhar, R. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.08.019 · Cited by 2
“It is most commonly caused by steroid administration leading to exogenous hypercortisolism [2].”
BackgroundAkkuş, G., Karagün, B., Cetinalp, N. E., Açıkalın, A., Odabaş, F., Evran, M., Sert, M., Zorludemir, S., & Tetıker, T. (2020) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.783225 · Cited by 2
Fernández, L. G., Ramos, R. J. A., Montenegro, A. M. R., Torrecilla, N. B., González, M. M., Moreno, D. M., Goñi, J. A., Weber, B., Guerra, A. L., Ishishi, Y. L. O., et al. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.10.013 · Cited by 2
Postoperative adrenal insufficiency in Conn’s syndrome—does it occur frequently?
Zelinka, T., Petrák, O., Waldauf, P., Zítek, M., Holaj, R., Forejtová, L., Michalský, D., Novák, K., Duskova, J., Springer, D., et al. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00618-0 · Cited by 2
Wang, B., Yang, Y., Yuan, H., & Li, X. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9536730 · Cited by 3
Polycystic Ovarian Syndrome: A Diagnosis of Exclusion
Wolf, J., Barnes, C., & Aubuchon, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8394-6_2 · Cited by 4
“15 μg/dL) is highly suggestive of Cushing’s syndrome, with sensitivity of 90–95 % and specifi city of 90–100 %, but results may be compromised in patients with depression or for occupations with disrupted sleep–wake cycles [ 26 , 27 ].”
BackgroundInfluentialSurgical Treatment of Cushing’s Disease
Tierney, T. S., & Swearingen, B. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_9 · Cited by 2
Competitive and compensatory effects of androgen signaling and glucocorticoid signaling
Harada, N., Inui, H., & Yamaji, R. (2015) · Receptors & Clinical Investigation · doi:10.14800/rci.785 · Cited by 2
“The long-term effects causing central adiposity are observed in patients with Cushing's syndrome [45] and in patients treated with exogenous corticosteroid treatment ([46]).”
Perera, N., Crawford, B., & Chua, E. L. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03869.x · Cited by 2
Menstrual Disorders and Hyperandrogenism in Adolescence
DiVall, S. A., & Rosenfield, R. L. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_25 · Cited by 2
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.